Plain-English translation of NCT05944237 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing HTL0039732, a new medication that works by blocking a natural process in the body that cancers use to escape your immune system. Researchers will test this medication alone and also combined with atezolizumab, an approved immunotherapy drug that helps your immune system recognize and attack cancer cells. The goal is to find the safest and most effective dose of the treatment.
Some cancers produce high levels of a natural substance called prostaglandin E2, which suppresses your immune system and allows the cancer to hide from it. This trial exists to see whether blocking this substance can help 'wake up' your immune system so it can fight back against the cancer more effectively.
You likely qualify if…
You likely don't qualify if…
You would take capsules of the medication by mouth, either alone or combined with an intravenous immunotherapy infusion, depending on which group you're assigned to. The trial involves multiple clinic visits for blood work, scans to measure your cancer, and possibly tumor biopsies to help researchers understand how the medication is working. The first phase focuses on finding the right, safe dose, while the second phase tests that dose in a larger group of patients with specific cancer types.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United Kingdom